Fibrolamellar Carcinoma — Trials

Fibrolamellar Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

21 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 18%
Top sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01215565	Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma(Fibrolam)	terminated	Phase 2	4	Assistance Publique - Hôpitaux de ParisOTHER	1	Mar 13, 2014	clinicaltrials

Data updated 22 days agoSource updated Mar 13, 2014source: clinicaltrials